Avalo Therapeutics appoints Kevin Lind to its Board of Directors
– USA, PA – Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, announced the appointment of Kevin Lind to its Board of Directors, bringing more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit.…